论文部分内容阅读
目的观察多西紫杉醇联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效和不良反应。方法蒽环类药物治疗失败的晚期乳腺癌患者32例,接受卡培他滨和多西紫杉醇联合方案化疗。卡培他滨2000mg/(m2.d),第1～14天;多西紫杉醇25～30mg/m2,第1、8、15天,21d为1个疗程,至少治疗2个疗程。结果完全缓解4例,部分缓解11例,稳定12例,进展5例,总有效率46.9%,平均TTP5.5个月。主要不良反应为骨髓抑制,胃肠道反应和手足综合征,Ⅲ+Ⅳ度白细胞下降15.6%,其余多为Ⅰ～Ⅱ毒性反应。结论多西紫杉醇联合卡培他滨治疗蒽环类药物耐药的晚期乳腺癌,有较好的疗效,毒性可以耐受,为有效的解救方案。
Objective To observe the efficacy and adverse reactions of docetaxel plus capecitabine in the treatment of anthracycline-resistant advanced breast cancer. Methods Thirty-two patients with advanced breast cancer who had failed anthracycline therapy were treated with capecitabine and docetaxel combined with chemotherapy. Capecitabine 2000mg / (m2.d), the first to 14 days; docetaxel 25 ~ 30mg / m2, the first 1,8,15 days, 21d for a course of treatment, at least two courses of treatment. Results of complete remission in 4 cases, partial remission in 11 cases, stable in 12 cases, progress in 5 cases, the total effective rate was 46.9%, the average TTP5.5 months. The main adverse reactions were myelosuppression, gastrointestinal tract reaction and hand-foot syndrome. The grade Ⅲ + Ⅳ leukocytes decreased by 15.6%, and the rest were mostly Ⅰ-Ⅱ toxicities. Conclusion Docetaxel combined with capecitabine in the treatment of anthracycline-resistant advanced breast cancer has good curative effect and toxicity, which is an effective rescue plan.